This shows that the rate of loss of p16 is substantially increased (P=0.05) with the advancement in tumor grade, comparable to Yang et al. (2004) and Alshaikhly et al. (2017) who showed loss of p16 expression with increasing tumor grade in urothelial carcinoma but Hashmi et al. (2019) found 59.6% cases of low-grade urothelial cancer had been identified negative expression which does not correspond with the present study (11, 28, 29). Here, CDKN2A is linked to neoplasm.